What Is Coluracetam?
Coluracetam is an experimental member of the racetam family of synthetic compounds. It is also known by the development codes MKC-231 and BCI-540. The compound was originally developed in Japan by Mitsubishi Tanabe Pharma, formerly associated with Mitsubishi Kagaku Corporation, during research into cognition and cholinergic neurotransmission. Unlike many racetams, coluracetam became notable because its principal proposed action is not simply modulation of acetylcholine receptors. Instead, preclinical work has focused on enhancement of high-affinity choline uptake, a transport process that supplies choline to nerve terminals for acetylcholine production.
Development later moved to BrainCells Inc., which investigated coluracetam in clinical research involving major depressive disorder, including people with an inadequate response to conventional antidepressant treatment. BrainCells reported development activity and clinical-trial results in the public domain, but coluracetam did not become an approved antidepressant, and the clinical evidence has not developed into a large, independently replicated literature. Much of the compound's current reputation therefore comes from animal research, mechanistic studies, limited early clinical data, and anecdotal reports. Claims about mood, vision, memory, or anxiety should be interpreted as hypotheses rather than established therapeutic effects.
Coluracetam is not approved by the United States Food and Drug Administration, the European Medicines Agency, or comparable authorities as a treatment for depression, anxiety, visual impairment, dementia, schizophrenia, or cognitive decline. Products sold online may be marketed as research chemicals or dietary supplements, but those labels do not guarantee identity, purity, stability, or legal status. The absence of approval is especially important because long-term human safety, drug interactions, reproductive effects, and effects in people with neurological or psychiatric illness have not been adequately characterized.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- The choline transporter is localized at the synaptic vesicles in cholinergic neurons.
Okuda, T., Haga, T., Kanai, Y., et al., 2000, Nature Neuroscience - The high-affinity choline transporter: a critical component of cholinergic neurotransmission.
Apparsundaram, S., Ferguson, S. M., Blakely, R. D., 2000, Journal of Neuroscience - Vesicular localization and activity-dependent trafficking of presynaptic choline transporters.
Ferguson, S. M., Bazalakova, M., Savchenko, V., et al., 2003, Journal of Neuroscience - The choline transporter and cholinergic signaling: implications for neurological disease.
English, B. A., Apparsundaram, S., 2012, Nature Neuroscience